Market Overview

UPDATE: Credit Suisse Initiates Pharmacyclics at Outperform on Pure Play Potential

Share:
Related PCYC
10 Biotech Stories You Might've Missed This Week
Mid-Day Market Update: Pharmacyclics Surges On Strong Preliminary 2014 Results; Fresh Market Shares Slip
With The Fed Fading Into The Shadows, Investors Look Overseas For New Catalysts (Seeking Alpha)

Credit Suisse initiated coverage on Pharmacyclics, Inc. (NASDAQ: PCYC) with an Outperform rating and a $79.00 price target.

Credit Suisse noted, "We believe that PCYC is the most derisked and investible pure play in the emerging oral lymphoma/leukemia drug class with blockbuster potential. The biggest remaining question is how large the could market be. We believe that experience with Revlimid and Gleevec provide strong evidence that worldwide markets likely exceed $5B, and ibrutinib is positioned to be both first-in-class and best-in-class in key market segments."

Pharmacyclics closed at $65.15 on Monday.

Latest Ratings for PCYC

DateFirmActionFromTo
Jan 2015JMP SecuritiesMaintainsMarket Outperform
Jan 2015CitigroupMaintainsBuy
Jan 2015BTIG ResearchInitiates Coverage onBuy

View More Analyst Ratings for PCYC
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (PCYC)

Around the Web, We're Loving...

Get Benzinga's Newsletters